Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock

被引：0
作者：
Delgado, M [1 ]
Gomariz, RP [1 ]
Martinez, C [1 ]
Abad, C [1 ]
Leceta, J [1 ]
机构：
[1] Univ Complutense Madrid, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2000年 / 30卷 / 11期
关键词：
neuroimmunomodulation; macrophage; sepsis; inflammation; VPAC agonist;
D O I：
10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Vasoactive intestinal peptide (VIP) is a neuropeptide that can modulate several immune aspects. Previous reports showed that VIP attenuates the deleterious consequences of septic shock by inhibiting the production of pro-inflammatory agents and stimulating the production of anti-inflammatory cytokines in activated macrophages. In this study, by using selective VIP agonists, we investigated the differential involvement of the VIP receptors in the anti-inflammatory role of VIP. Both the type 1 VIP receptor (VPAC1) agonist, [K-15, R-16, L-27] VIP [1-7]-GRF [8-27], and the type 2 VIP receptor (VPAC2) agonist, Ro25-1553, protected mice from lethal endotoxemia by inhibiting the macrophage-derived pro-inflammatory mediators IL-6, TNF-alpha, IL-12 and NO, and by stimulating the production of the anti-inflammatory cytokine IL-10. In addition, both VIP and VPAC1 agonist, but not the VPAC2 agonist, reduced in vitro and in vivo the expression of the co-stimulatory B7.1/B7.2 molecules, and the subsequent stimulatory activity for T helper cells in stimulated macrophages. The higher effectiveness of the VPAC1 agonist compared with the VPAC2 agonist suggests that VPAC1 is the major mediator of the anti-inflammatory action of VIP. Since VIP and the two agonists appear to affect multiple cytokines and inflammatory factors, they might provide a more efficient therapeutical alternative to the use of specific cytokine antibodies or antagonists.
引用
收藏
页码：3236 / 3246
页数：11
相关论文
共 43 条
[21]   INTERLEUKIN-12 IS PRODUCED IN-VIVO DURING ENDOTOXEMIA AND STIMULATES SYNTHESIS OF GAMMA-INTERFERON [J].
HEINZEL, FP ;
RERKO, RM ;
LING, P ;
HAKIMI, J ;
SCHOENHAUT, DS .
INFECTION AND IMMUNITY, 1994, 62 (10) :4244-4249
[22]   Structure and evolution of the extended B7 family [J].
Henry, J ;
Miller, MM ;
Pontarotti, P .
IMMUNOLOGY TODAY, 1999, 20 (06) :285-288
[23]   Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects [J].
Hernanz, A ;
Tato, E ;
DelaFuente, M ;
deMiguel, E ;
Arnalich, F .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 71 (1-2) :25-30
[24]   INTERLEUKIN-10 PROTECTS MICE FROM LETHAL ENDOTOXEMIA [J].
HOWARD, M ;
MUCHAMUEL, T ;
ANDRADE, S ;
MENON, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (04) :1205-1208
[25]   THE B7 AND CD28 RECEPTOR FAMILIES [J].
JUNE, CH ;
BLUESTONE, JA ;
NADLER, LM ;
THOMPSON, CB .
IMMUNOLOGY TODAY, 1994, 15 (07) :321-331
[26]   Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma [J].
Kaltreider, HB ;
Ichikawa, S ;
Byrd, PK ;
Ingram, DA ;
Kishiyama, JL ;
Sreedharan, SP ;
Warnock, ML ;
Beck, JM ;
Goetzl, EJ .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (02) :133-144
[27]   MACROPHAGES AND INFLAMMATORY MEDIATORS IN TISSUE-INJURY [J].
LASKIN, DL ;
PENDINO, KJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1995, 35 :655-677
[28]   THE ROLE OF THE CD28 RECEPTOR DURING T-CELL RESPONSES TO ANTIGEN [J].
LINSLEY, PS ;
LEDBETTER, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 :191-212
[29]   THE VIP(2) RECEPTOR - MOLECULAR CHARACTERIZATION OF A CDNA-ENCODING A NOVEL RECEPTOR FOR VASOACTIVE-INTESTINAL-PEPTIDE [J].
LUTZ, EM ;
SHEWARD, WJ ;
WEST, KM ;
MORROW, JA ;
FINK, G ;
HARMAR, AJ .
FEBS LETTERS, 1993, 334 (01) :3-8
[30]   INTERLEUKIN-10 CONTROLS INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR PRODUCTION DURING EXPERIMENTAL ENDOTOXEMIA [J].
MARCHANT, A ;
BRUYNS, C ;
VANDENABEELE, P ;
DUCARME, M ;
GERARD, C ;
DELVAUX, A ;
DEGROOTE, D ;
ABRAMOWICZ, D ;
VELU, T ;
GOLDMAN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (05) :1167-1171
12345